NuCana Discontinues Phase 2 Colorectal Cancer Study
![NuCana Discontinues Phase 2 Colorectal Cancer Study](https://investorshangout.com/images/blog/ihnews-NuCana%20Discontinues%20Phase%202%20Colorectal%20Cancer%20Study.jpg)
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study
NuTide:323 Study Discontinued After Initial Analysis
Ongoing Studies Show Promise with NUC-7738 and Pembrolizumab
NuCana plc (NASDAQ: NCNA) has announced key updates regarding its clinical studies involving innovative treatments for colorectal cancer. The company has decided to discontinue the NuTide:323 study, based on recommendations from the study's Steering Committee after a planned initial analysis. Despite assessing favorable conditions for the control arm, it was determined that the combination treatment of NUC-3373 with leucovorin, irinotecan, and bevacizumab (NUFIRI+bev) would likely not meet the primary objective of superior Progression Free Survival (PFS) compared to the control regimen, which includes 5-FU, leucovorin, irinotecan, and bevacizumab (FOLFIRI+bev). Throughout the trial, the regimens were well tolerated, with only a minor percentage of patients choosing to discontinue treatment due to side effects.
Hugh S. Griffith, the Founder and Chief Executive Officer of NuCana, expressed his disappointment regarding the outcomes of the NuTide:323 study. He acknowledged the challenges present in developing effective treatments for complex cancers, such as metastatic colorectal cancer, while reassuring stakeholders of the valuable insights gained from this study. Griffith emphasized the company's commitment to further developing potential treatment options using the data collected.
Professor Josep Tabernero, MD, PhD, who leads the Medical Oncology Department at Vall d´Hebron University Hospital and chairs the Steering Committee for the NuTide:323 study, highlighted their aspiration to establish NUC-3373 as an effective alternative to conventional therapies like 5-FU. He reflected on the dissatisfaction shared by the study team concerning the study's results, which did not align with their initial expectations.
Despite the setback with the NuTide:323 study, Griffith affirmed that this development will not derail the ongoing NuTide:303 study. In this trial, NUC-3373 is being evaluated in combination with pembrolizumab for patients with solid tumors and in another cohort with docetaxel for those battling lung cancer. Furthermore, excitement surrounds NUC-7738, a novel anti-cancer agent that effectively alters gene expression within cancer cells while targeting various facets of the tumor microenvironment. Upcoming presentations at the ESMO annual conference will detail the data from the Phase 2 segment of the NuTide:701 study, primarily focusing on NUC-7738 combined with pembrolizumab for melanoma patients.
About NuCana
NuCana is at the forefront of biopharmaceutical innovation, driven to enhance cancer treatment outcomes through its proprietary ProTide technology. This transformative approach seeks to optimize the delivery and efficacy of established chemotherapy agents, specifically nucleoside analogs, which often fall short in effectiveness and safety profiles. NuCana's diverse pipeline showcases treatments like NUC-3373 and NUC-7738, with NUC-3373 currently under examination in two clinical studies: the NuTide:302 study, focusing on metastatic colorectal cancer, and the NuTide:303 study for advanced solid tumors.
NUC-7738 represents a groundbreaking advancement in cancer therapy, targeting RNA polyadenylation and significantly impacting gene expression while addressing the tumor microenvironment. The ongoing Phase 2 trials for NUC-7738 seek to establish its efficacy as both a monotherapy and in conjunction with pembrolizumab for patients with various advanced solid tumors.
Contact Information
For more information about NuCana plc or to inquire about their studies, please reach out to:
NuCana plc
Hugh S. Griffith
Chief Executive Officer
+44 131-357-1111
info@nucana.com
ICR Westwicke
Chris Brinzey
+1 339-970-2843
chris.brinzey@westwicke.com
Frequently Asked Questions
What led to the discontinuation of the NuTide:323 study?
The NuTide:323 study was discontinued after a planned analysis indicated that the combination treatment was unlikely to achieve its primary goal of improved Progression Free Survival compared to the control treatment.
What does NuCana plan to do following the study's results?
NuCana plans to utilize insights gained from the study to inform future development options for their therapies, particularly NUC-3373.
Are there any ongoing studies related to NUC-3373?
Yes, NUC-3373 is currently being examined in two separate studies: NuTide:302 for metastatic colorectal cancer and NuTide:303 for advanced solid tumors.
What are the key features of NUC-7738?
NUC-7738 is a novel anti-cancer agent that disrupts RNA polyadenylation, affecting gene expression and targeting various aspects of the tumor microenvironment.
How can stakeholders stay informed about NuCana's progress?
Stakeholders can stay updated by following the announcements and presentations from NuCana, especially those regarding upcoming conferences and study results.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Electric Submersible Pumps Market to Reach USD 29.9 Billion
- InterCure Reports Strong Financial Performance in 2024
- Cerro Grande Mining Corporation Reports Q3 2024 Financial Results
- ARCpoint Conference Call for Q2 2024 Financial Results
- AIP Realty Trust Reports Second Quarter 2024 Financial Results
- Current Water Technologies Reports Q2 2024 Financial Results
- Constellation Brands Announces Q2 Fiscal 2025 Financial Results
- Meritage Homes Unveils 2023 Environmental and Governance Report
- Dell Technologies Reports Strong Q2 Revenue Growth
- BIGG Digital Assets Inc. Announces Strong Q2 2024 Results
- StateHouse Reports Significant Growth in Q2 2024 Financials
- Red White & Bloom Announces Strong Q2 2024 Results
- Pan American Energy Completes Phase 2 Earn-In for Big Mack
- International Money Express Secures $425 Million Credit Facility
- Kane Biotech Reports Strong Q2 2024 Financial Performance
- IBEX Limited Announces FY2024 Financial Results Details
- ARMOUR Residential REIT Announces Dividend Rate for September 2024
- Rail Vision Releases Strong Financial Results for H1 2024
- Great Elm Group Announces Fiscal 2024 Financial Results
- 3D Systems Corp Q2 2024 Financial Highlights
- Nvidia Reports Q2 Results: Is the Stock a Buy Opportunity?
- DMG Blockchain Solutions to Showcase at 2024 Gateway Conference
- A-Mark Precious Metals Reports Preliminary Q4 and Full Year 2024 Results
- Inari Medical Reveals PEERLESS Trial Data at TCT 2024
- Artiva Biotherapeutics' Q2 2024 Highlights and Results
Recent Articles
- Cerro Grande Mining Corporation Reports Q3 2024 Financial Results
- NVIDIA Schedules Event for Financial Community Engagement
- Petrus Resources Shares Monthly Activity Update
- Innovative Ketamine-Based Treatment Collaboration
- Clearmind Medicine's Patent Application for Ketamine Innovations
- California Water Service Group Celebrates Top Workplace Honor
- Iceland Seafood International Completes Bill Auction
- Bureau Veritas Reports Shares and Voting Rights
- Hargreave Hale AIM VCT PLC Update on Share Purchase
- Havila Shipping ASA: Written Resolution Details for HAVI04 and HAVI07
- Psychemedics Corporation Introduces Ketamine Hair Testing
- Biomerica Reports Year-End Results for Fiscal 2024
- Dermal Filler Market Growth and Future Prospects
- Femasys Secures CE Mark and Canadian Approval for FemVue MINI
- Glycerin Market Growth Insights and Key Players
- SSCP Lager Bidco AB Reports Strong Q2 Performance
- Nobel Resources Corp. Announces Major Private Placement
- Top AI Stocks to Consider for Future Growth
- Exploring the Exclusive Amex Centurion Card Benefits
- Hydraulic Rescue Tools Market Growth Insights
- Barricade Building Products Expands Distribution Network
- Tarsus Pharmaceuticals Participates in Healthcare Conference
- Silvano Fashion Group Reports Q2 and 6M 2024 Financial Performance
- Greystone Housing Impact Investors LP Shares Schedule K-3
- IREN Reports Strong FY24 Financial Performance